- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Walmart, CVS to halt filling prescriptions for controlled substances
![Walmart, CVS to halt filling prescriptions for controlled substances Walmart, CVS to halt filling prescriptions for controlled substances](https://medicaldialogues.in/h-upload/2022/05/27/750x450_177305-walmart.webp)
New Delhi: Walmart Inc and CVS Health Corp said on Wednesday they will stop filling prescriptions for controlled substances issued by telehealth startups Cerebral Inc and Done Health.
Cerebral and Done are known for treating patients with ADHD, prescribing stimulants such as Adderall.
Walmart confirmed the move to Reuters and said the decision was made after an audit and compliance process.
CVS said it will not accept prescriptions for controlled substances issued by the startups effective May 26, as a result of a review it conducted on the telehealth firms and after it was "unable to resolve concerns we have with Cerebral and Done Health."
Cerebral and Done did not respond to Reuters requests for comment.
According to a Wall Street Journal report earlier this month, Cerebral had been issued a subpoena by federal prosecutors as part of an investigation into possible violations of the Controlled Substances Act.
Read also: Traders body accuses online pharmacies of predatory pricing
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story